NA
LGND icon

Navellier & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Navellier & Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,931
Closed -$269K – 259
2020
Q1 		$269K Hold
5,931
– – 0.06% 187
2019
Q4 		$386K Sell
5,931
-713
-11% -$47.6K 0.06% 210
2019
Q3 		$413K Buy
6,644
+64
+1% +$4.02K 0.07% 192
2019
Q2 		$469K Hold
6,580
– – 0.07% 184
2019
Q1 		$516K Sell
6,580
-32
-0.5% -$2.42K 0.08% 160
2018
Q4 		$560K Sell
6,612
-12,930
-66% -$1.38M 0.1% 136
2018
Q3 		$3.35M Buy
19,542
+3,754
+24% +$566K 0.43% 65
2018
Q2 		$2.04M Buy
15,788
+1,295
+9% +$145K 0.28% 109
2018
Q1 		$1.49M Buy
14,493
+7,857
+118% +$777K 0.23% 119
2017
Q4 		$567K Buy
+6,636
New +$575K 0.11% 172
2017
Q3 		– Sell
-6,636
Closed -$503K – 278
2017
Q2 		$503K Sell
6,636
-1,066
-14% -$74.6K 0.08% 181
2017
Q1 		$509K Sell
7,702
-10,672
-58% -$702K 0.07% 186
2016
Q4 		$1.17M Buy
18,374
+2,298
+14% +$145K 0.19% 128
2016
Q3 		$1.02M Buy
16,076
+8,010
+99% +$588K 0.15% 128
2016
Q2 		$600K Sell
8,066
-1,164
-13% -$86.4K 0.09% 128
2016
Q1 		$617K Sell
9,230
-6,202
-40% -$377K 0.08% 116
2015
Q4 		$1.04M Buy
15,432
+8,613
+126% +$532K 0.11% 82
2015
Q3 		$364K Buy
+6,819
New +$414K 0.04% 199
2014
Q3 		– Sell
-17,351
Closed -$674K – 345
2014
Q2 		$674K Sell
17,351
-8,563
-33% -$347K 0.03% 147
2014
Q1 		$1.09M Sell
25,914
-13,860
-35% -$578K 0.05% 91
2013
Q4 		$1.3M Buy
+39,774
New +$1.3M 0.06% 81

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Navellier & Associates's LGND Position: Q2 2020 in Review

Navellier & Associates sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 5,931 shares — an estimated $269K sold.

Navellier & Associates first reported a position in LGND in Q4 2013 and held it in 21 quarters. The position peaked at $3.35M in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

  • Navellier & Associates reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Navellier & Associates sold 5,931 Ligand Pharmaceuticals shares in Q2 2020, an estimated $269K.
  • Navellier & Associates first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 21 quarters.
  • Navellier & Associates's Ligand Pharmaceuticals position peaked at $3.35M in Q3 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Navellier & Associates's 13F filing for Q2 2020, filed 12 Aug 2020.